化浊解毒法对肝纤维化大鼠TGF-β/Smad信号转导通路的影响
|
摘要
肝纤维化(hepatic fibrosis,HF)是指肝细胞发生坏死或炎症刺激时,肝脏内纤维结缔组织增生与分解失衡,从而在肝内异常沉积的病理过程,是多种慢性肝病的重要病理特征和发展至肝硬化的必经阶段。2006年美国第三届肝纤维化专题会议明确了肝纤维化是可逆的。Hans Popper教授说:“谁能阻止或延缓肝纤维化,谁将能医治大多数慢性肝病”。
肝纤维化发生的关键是肝星状细胞(hepatic stellate cell,HSC)的激活及其激活后细胞外基质(extracellular matrixc,ECM)异常表达。从细胞因子及其信号转导角度研究药物的干预机制,有利于促进HF治疗学研究。转化生长因子-β1(transforming growth factor-beta1-1,TGF-β1)是最重要的促肝纤维化细胞因子之一,具有抑制肝细胞增殖、诱导肝细胞凋亡,激活HSC、促进其产生ECM等作用,TGFβ/Smad信号转导通路是TGFβ发挥这些生物效应重要的信号转导通路。
目前临床仍缺乏高效、无明显毒副作用的治疗HF的西药。中医药通过多途径、多环节、多靶点的综合药理学作用在抗HF方面展现出优势,显示了良好的前景。李佃贵教授经过多年的临床实践和基础研究,结合当今疾病模式及疾病谱的变化,提出以“浊毒”立论治疗肝纤维化的理论,并应用化浊解毒调肝法进行治疗,取得较好疗效。依据此理论确立的肝复健方能显著改善HF、慢性肝炎患者临床症状,促进HF指标的恢复;肝复健方能明显改善HF模型大鼠肝功能、抑制肝纤维化大鼠血清HA、LN、Ⅳ-C、PCIII水平,抑制胶原纤维增生等作用。本课题以肝纤维化大鼠模型,以秋水仙碱为对照,观察肝复健方对HF大鼠肝脏TGF-β1及其受体、Smad2/3、Smad4、Smda7的表达情况,探讨其对TGF-β/Smad信号传导通路的影响,旨在对本方抗HF的药效和可能的作用机制作进一步的研究,为其临床应用提供实验依据。本实验分为以下五部分:
第一部分浊毒理论与肝纤维化
目的:以浊毒理论为依据探讨其在肝纤维化治疗中的地位,进而提出新的观点与治疗方法。
方法:温习、回顾了中医理论中浊毒源流,提出浊毒相关为害是肝纤维化的主病机,系统总结了肝纤维化浊毒特性的临床表现、基本治法、用药规律及兼夹证的治疗。
结果:梳理了浊毒之源流,探讨了肝纤维化与浊毒的关系,以及化浊解毒调肝法提出的理论依据,从临床论证了化浊解毒调肝方药治疗肝纤维化的可行性。
结论:浊毒是肝纤维化形成和进展过程中重要的始动因素和关键环节,临床上应用化浊解毒法不仅能改善其症状,还可恢复肝脏生理特性,截断或逆转肝脏病理性改变。
第二部分肝复健方对肝纤维化大鼠肝脏病理组织学的影响
目的:将肝复健方应用于造模成功的HF大鼠,观察肝复健方对HF大鼠一般情况和病理组织学的影响。
方法:健康雄性SD大鼠60只,适应性喂养一周,随机分为正常组(Normal)10只,造模组50只。除正常组外,造模组采用腹腔注射未灭活猪血清法造模,每只大鼠每次注射猪血清0.5 ml,每周2次,共8周。造模成功大鼠分为:模型组,肝复健方小剂量组(以下简称GFJL),肝复健方中剂量组(以下简称GFJM),肝复健方大剂量组(以下简称GFJH),秋水仙碱组,每组均10只。GFJL给予含1.5 g生药/ml水煎剂2ml灌胃;GFJM给予含2.25 g生药/ml水煎剂2ml灌胃;GFJH给予含3.0 g生药/ml水煎剂2ml灌胃;秋水仙碱组给予0.154 g/kg·d灌胃;空白组、模型组均给予等量生理盐水灌胃。各组均灌胃至12周末。造模用药期间观察大鼠一般情况。于12周结束时,断颈处死各组大鼠,留取大鼠肝组织,采用苏木精-伊红染色(HE染色)和Masson染色(胶原纤维特殊染色法)观察肝组织病理形态学改变并进行大鼠肝纤维化病变半定量分析。
结果:
1一般情况观察
肝复健方可明显改善HF大鼠的精神状态、饮食、皮毛色泽,增加其体重。
2肝脏大体形态观察
正常组大鼠肝脏质地柔软,表面光滑。模型组大鼠肝脏质地坚韧,表面粗糙,颜色晦暗,有些可见颗粒状的小结节。秋水仙碱组及肝复健方药物治疗组大鼠肝表面较模型组光滑,质地较柔软。
3肝复健方对肝纤维化大鼠肝组织病理的影响
正常组肝小叶结构完整,肝细胞围绕中央静脉呈放射状排列,无变性坏死,无纤维组织增生。模型组肝小叶结构严重破坏,肝细胞广泛坏死伴炎性细胞浸润,纤维组织大量增生并形成纤维间隔。与模型组比较,各药物治疗组肝小叶结构破坏明显减轻,肝脏胶原纤维增生亦明显减轻,纤维条索疏松变窄。肝细胞水肿好转,变性情况明显改善,炎细胞浸润减少。其中肝复健方高、中剂量组肝脏结构改善较为明显。
4大鼠肝纤维化病变半定量分析
按肝纤维化病变半定量分析判断标准的计分标准,正常组大鼠纤维化程度为0,模型组大鼠纤维化程度为(15.76±0.33),秋水仙碱组大鼠纤维化程度为(5.46±0.20),GFJL大鼠纤维化程度为(11.54±0.36),GFJM大鼠纤维化程度为(9.6±0.16),GFJH大鼠纤维化程度为(5.2±0.12)。与模型组比较,秋水仙碱组、GFJL、GFJM、GFJH大鼠纤维化程度均明显减轻,差异有统计学意义(P<0.05)。
结论:肝复健方能改善HF大鼠一般状况,能显著减轻大鼠肝组织炎症活动度及纤维化程度,体现出较强的保肝、抗HF作用。
第三部分肝复健方对肝纤维化大鼠肝组织TGF-β1的影响
目的:探讨肝复健方对HF大鼠TGF-β1的影响。方法:免疫组织化学法和RT-PCR法分别检测HF大鼠肝组织TGF-β1的表达。
结果:
1肝复健方对大鼠肝组织TGF-β1蛋白表达的影响
正常肝组织中TGF-β1蛋白微弱表达,显色极淡。模型组较正常组TGF-β1阳性信号明显增强;不同剂量肝复健方组TGF-β1蛋白的表达较模型组明显减少(p<0.05),GFJH作用最为明显;秋水仙碱组TGF-β1蛋白的表达较模型组降低(p<0.05)。
2肝复健方对大鼠肝组织TGF-β1mRNA表达的影响
与正常对照组相比,模型组、秋水仙碱组和肝复健方大、中、小剂量组TGF-β1mRNA的表达均明显增强,差异有统计学意义(p<0.05)。与模型对照组相比,秋水仙碱组和肝复健方大、中、小剂量组TGF-β1mRNA表达明显减弱,差异有统计学意义(p<0.05)。且肝复健方大、中剂量组优于秋水仙碱组(p<0.05)。
结论:肝复健方可能通过降低肝组织TGF-β1蛋白及基因的表达而达到抗纤维化的作用。
第四部分肝复健方对肝纤维化大鼠肝组织TβRI、TβRII的影响
目的:探讨肝复健方对HF大鼠TβRI、TβRII表达的影响。方法:免疫组织化学法和RT-PCR法分别检测HF大鼠肝组织TβRI、TβRII的表达。
结果:
1肝复健方对大鼠肝组织TβRI、TβRII蛋白表达的影响
正常对照组肝细胞和间质细胞可见TβRI和TβRII阳性染色,模型组TβRI和TβRII阳性染色显著增强(P<0.05),尤以纤维增生组织和炎性细胞周围多见。与正常组相比,模型组和各治疗组表达明显升高(P<0.05),而与模型组比较,秋水仙碱组和肝复健方各剂量组大鼠肝组织TβRI和TβRII表达则明显降低(P<0.05);各治疗组比较,肝复健方大、中剂量组优于秋水仙碱组(P<0.05)。
2肝复健方对大鼠肝组织TβRI、TβRII mRNA表达的影响
与正常对照组相比,模型对照组、秋水仙碱组和肝复健方大、中、小剂量组TβRI和TβRIImRNA的表达均明显增强,差异有统计学意义(p<0.05)。与模型对照组相比,秋水仙碱组和肝复健方大、中、小剂量组TβRI和TβRIImRNA表达明显减弱,差异有统计学意义(p<0.05)。且肝复健方大、中剂量组优于秋水仙碱组(p<0.05)。
结论:肝复健方能够显著抑制HF大鼠肝组织TβRI、TβRII型受体蛋白及基因的表达,从而抑制HF的发生、发展。
第五部分肝复健方对肝纤维化大鼠肝组织Smads表达的影响
目的:探讨肝复健方对Smad2/3,Smad4,Smad7蛋白表达的影响,结合二、三、四部分,观察其对TGF-β/samd信号通路的影响。
方法:Western blot检测HF大鼠肝组织Smad2/3,Smad4,Smad7的表达。
结果:
1肝复健方对大鼠肝组织Smad2/3、Smad4蛋白表达的影响(1)所有实验组大鼠肝组织中Smad2/3、Smad4的表达量均高于正常对照组(P<0.05);(2)肝复健方各剂量组及秋水仙碱组与模型组相比Smad2/3、Smad4的表达量有显著性降低(P<0.05);(3) GFJL与秋水仙碱组相比Smad2/3、Smad4表达量均无显著性差异(P>0.05);肝复健方中、大剂量组分别与秋水仙碱组相比Smad2/3、Smad4的表达量有显著性降低(P<0.05);(4)GFJH与GFJM相比Smad2/3、Smad4表达量有下降趋势,但无显著性差异(P>0.05)。
2肝复健方对大鼠肝组织Smad7蛋白表达的影响(1)所有实验组大鼠肝组织中Smad7的表达量均低于正常对照组(P<0.05)。(2)肝复健方各剂量组及秋水仙碱组与模型组相比Smad7的表达量显著升高(P<0.05)。(3)GFJL与秋水仙碱组相比Smad7表达量均无显著性差异(P>0.05);肝复健方中、大剂量组分别与秋水仙碱组相比Smad7的表达量显著升高(P<0.05)。(4)GFJH与GFJM相比Smad7表达量有上升趋势,但无显著性差异(P>0.05)。
结论:肝复健方能够抑制受体活化性蛋白smad2和smad3的表达,下调通用性蛋白Smad4的表达,促进抑制性蛋白Smad7的表达,抑制HF大鼠肝脏中TGF-β/smad信号传导通路的激活,从而抑制肝纤维化的发生和发展。
Hepatic fibrosis (HF)is a pathologic process that every kind of disease cause liver injure and inflammation. Its essense is excessive deposition of extracellular matrix(ECM) components in liver,which occurs due to an imbalance between the production and degradation of matrix. It is the hallmark of most chronic liver diseases. The United States 3th liver fibrosis conferences in 2006 indicated that HF is reversible. Professor Hans Popper says:”Who can prevent or delay liver fibrosis, who will be able to cure most chronic liver disease.”
The activation and proliferation of hepatic stellate cell (HSC), which are the major source of ECM, are the crucial event to liver fibrosis. It is advantageous in HF treatment from the cell factor and its signal pathways to study mechanism of drug intervention.Transforming growth factor-beta1-1 (TGF-β1)is one of the most important Hepatic Fibrosis cell factors, can inhibition of hepatocyte proliferation, induce hepatocyte apoptosis, activate HSC,promote formation of ECM.TGF-β1 exerts biological effect mainly through TGF-β/samd signal pathway.
At present clinical still lackes highly effective and no obvious poisonous side effect medicine to treat HF.Traditional Chinese Medicine has seen significant advancement against liver fibrosis. After many years clinical practices and experiment research, combining with current disease pattern and disease spectrum changes,professor Li dian-gui advances the zhuodu theory , applies this theory to treat Hepatic Fibrosis patients ,which obtaining the good curative effect.Ganfujian formula based on zhuodu theory can improve patients’clinical findings, inhibiting inflammatory reaction and fibroplasias to promote the reversion of hepatic fibrosis. The experimental study indicated that,it can obviously reduce HF rat blood serum HA、LN、Ⅳ-C、PCⅢ,reduces the liver inflammation and the fibrosis degree.We still used Hepatic Fibrosis rat’s model, taking the colchicine as the comparison, to determine if Ganfujian formula could inhibit the expression of TGFβ1,TβRI,TβRII,smad2,smad3 and promote the expression of smad7 and then intercepts TGF-β/Samd signal pathway,.This provides scientific evidence for clinic to apply Ganfujian formula in treating cirrhosis. This experiment was separated into five parts:
Part one ZhuoDu theory and Hepatic Fibrosis
Objective: The aim was to study the effect of The ZhuoDu theory in the position of therapy for Hepatic Fibrosis in order to proposes the new viewpoint and the treatment method for HF.
Methods: Reviewed zhuodu’s source and course in the Chinese medicine theory,put forward that the main pathogenesis of Hepatic Fibrosis was zhuodu,and made a systematic summarization on the characteristics of Hepatic Fibrosis,symptoms,general therapies and the treatment of combined syndromes.
Results: We compiled the history of zhuodu ,discussed the relations of Hepatic Fibrosis and zhuodu, searched the treatment of huozhuo jiedu tiaogan theoretical basis,put forward that Hepatic Fibrosis’s main pathogenesis was zhuodu. Clinical curative effect proved that zhuodu theory has a positive position in treatment methods of Hepatic Fibrosis.
Conclusion: Zhuodu closely links with Hepatic Fibrosis in etiology and pathogenesis, also is it’s main pathogenesis.The therapy of huazhuo jiedu used in clinic can not only relieve the symptoms,but also restore the liver physiology characteristic and reversal liver pathology changes.
Part two Effect of Ganfujian formula on liver histopathology in HF rats
Objective: The aim was to observe Ganfujian formula’s effect on rats’ordinary circumstances and change of liver histopathology in HF rats.
Methods:Sixty male Sprague-Dauley rats were selected in this experiment.The animals were randomly divided into normal group(10 rats)and HF model group(50 rats).Besides the normal group, pig’s serum(0.5ml per mouse,twice a week)was established in rats by intraperitoneal injection for eight weeks. The rats of HF model were randomly divided into five groups: the model group,colchicines group,Ganfujian formula low dose group(GFJL), Ganfujian formula of medium dose group(GFJM) and Ganfujian formula of high dose group(GFJH)with 10 rats for each group. After HF models were made successfully,the drugs started be given to the rats according to adult dosage 5,15,20 times,respectively,once daily.The rats were respectively treated with Ganfujian low dose(1.5g crude-drug/ml),Ganfujian middle dose(2.25g crude-drug/ml),Ganfujian high dose(3.0g crude-drug/ml) and colchicine(0.154g/kg·d) intragastrically,the normal group and the model group were given physiological saline by gavage.Each group was given the medicine for 12 weeks. Observed rats’ordinary circumstances.All animals were killed ,the specimens were taken and the degree of hepatic fibrosis was judged by routine haematoxylin-eosin staining and Masson staining. Fibrosis score was calculated by semi-quantitative analysis of liver histopathology.
Results:
1 Rat ordinary circumstances observation
The rat ordinary circumstances observation demonstrated that,The strong 1iver fries by the stasis may obviously improve the HF rat’s state of mind,the diet, the superficial knowledge luster,increases its body weight.
2 Gross findings
Livers of control group were tender and smooth.The ones of model group were hard,coarse and tarnish,with some observable small nodules, whereas the ones of drug groups were smooth and tender.
3 Effect of Ganfujian formula to pathomorphology in hepatic fibrosis rats
The structure of hepatic lobule were integrated hepatic cord radially ranged as the center of navel vein. There was not degeneration and necrosis in liver tissue.There was not collagen proliferation.Compared with normal group,the model control rats had obvious liver inflammation including degeneration,necrosis,fibrosis and collagen proliferation.Pseudolobule proliferation could be seen in individual animal. Compared with model group,in various drug groups,the destructions were lightened,proliferatio ns of collagen fibers were also lightened,fiber cords were loosened and narrowed.Swelling of liver cells and degeneration alleviated,infiltrating cells decreased.These improvements were more significant in high and medium-dose GFJ groups.
4 Semi-quantitative analysis of liver histopathology in HF rats
According to HF semi-quantitative analysis standard,fibrosis score was evaluated on the liver tissue sections performing with HE and Reticulation's stain.The fibrosis score of normal group was 0,model group was 15.76±0.33, colchicines group was 5.46±0.20, GFJL was 11.54±0.36, GFJM was 9.6±0.16, GFJH was 5.2±0.12. Compared with model group, the fibrosis score all decreased in colchicines group, GFJL, GFJM and GFJH(p<0.05).
Conclusion:Ganfujian formula can improve the HF rat’s ordinary circumstances and obviously reduce the rat liver organization inflammation activity and the fibrosis degree,presents the good local constable liver,the anti-HF function.
Part three Effect of Ganfujian formula on TGF-β1 in HF rats
Objective: The aim was to explore Ganfujian formula’s effect on expression of TGF-β1 in HF rats.
Methods: TGFβ1 protein and mRNA expression were determined by using immunohistochemical technique and RT-PCR.
Results:
1 Experimental study on Ganfujian Formula effect on TGF-β1 protein of the hepatic fibrosis rats
Less positive expression of TGF-β1 cell can be seen in the liver tissue of rats form normal group.The expression of TGF-β1 was strongly positive in model group. The cell proportion of TGF-β1 cell expression in the liver tissue of rats form model group were significantly higer than that of the normal group,which were manifested by the unsymmetric brown yellow particulates.The protein level of TGF-β1 of hepatic fibrosis rats could be decreased from Ganfujian group and colchicines group significantly.The effect of GFJH group was better than that others group.
2 Experimental study on Ganfujian formula effect on TGF-β1 mRNA of the hepatic fibrosis rats
Compared with normal group, the level of TGF-β1 mRNA all increased in model group ,Ganfujian group and colchicines group(p<0.05).But the level of TGF-β1 mRNA decreased in Ganfujian group and colchicines group as compared with that in model group(p<0.05),in which,the reduction in medium dose group and high dose group were more than colchicines group(p<0.05).
Conclusion: Ganfujian formula possibly reduce or prevent hepatic fibrosis through decreasing the expression of TGF-β1 protein and mRNA. Part four Effect of Ganfujian formula on TβRI,TβRII in HF rats
Objective: The aim was to explore Ganfujian formula’s effect on expression of TβRI,TβRII in HF rats.
Methods: TβRI,TβRII protein and mRNA expression were determined by using immunohistochemical technique and RT-PCR, respectively.
Results:
1 Expression of TβRI,TβRII protein in liver tissue
TβRI,TβRII protein expressed in hepatocellular and interstitial cells. The expression of TβRI,TβRII protein in model group was stronger than which in normal group(P<0.05), TβRI,TβRII protein especially expressed around fibre hyperplasia and inflammatory cells.Compared with normal group,the expression of TβRI,TβRII protein in other groups was stronger(P<0.05).Compared with model group,the expression of TβRI,TβRII protein in Ganfujian groups and colchicines group was significantly lighter(P<0.05).The expression of TβRI,TβRII protein in GFJH group and GFJM group were lighter than that of colchicines group, there were significantly difference among those groups(P<0.05).
2 Expression of TβRI,TβRII mRNA in liver tissue
Compared with normal group,the expression of TβRI,TβRII mRNA in other groups was stronger(P<0.05).Compared with model group,the expression of TβRI,TβRII mRNA in Ganfujian groups and colchicines group was significantly lighter(P<0.05).The expression of TβRI,TβRII mRNA in GFJH group and GFJM group were lighter than that of colchicines group, there were significantly difference among those groups(P<0.05).
Conclusion: Ganfujian formula can significantly inhibits the expression of TGFβ1 receptors’protein and mRNA.
Part five Effect of Ganfujian formula on Smads in HF rats
Objective: The aim was to explore Ganfujian formula’s effect on expression of Smads’protein in HF rats.Combined with part two,three and four, Our study is to determine if Ganfujian formula intercepts TGF-β/Samd signal pathway.
Methods: Western blotting was used for detecting the protein expression level of Smad2/3,Smad4,Smad7, respectively.
Results:
1 Expression of Smad2/3, Smad4 protein in liver tissue
Compared with normal group,the expression of Smad2/3, Smad4 in other groups was stronger(P<0.05).Compared with model group,the expression of Smad2/3, Smad4 in Ganfujian groups and colchicines group was significantly lighter(P<0.05).Compared with colchicines group, the expression of Smad2/3, Smad4 in GFJM group and GFJH group was significantly lighter(P<0.05),and there was no difference between colchicines group and GFJL group(P>0.05). The expression of Smad2/3, Smad4 in GFJH group was lighter than that of GFJM group,but there was no difference between two groups(P>0.05).
2 Expression of Smad7 protein in liver tissue
Compared with normal group,the expression of Smad7 in other groups was lower(P<0.05).Compared with model group,the expression of Smad7 in Ganfujian groups and colchicines group was significantly stronger(P<0.05).Compared with colchicines group, the expression of Smad7 in GFJM group and GFJH group was significantly stronger(P<0.05),and there was no difference between colchicines group and GFJL group(P>0.05). The expression of Smad7 in GFJH group was stronger than that of GFJM group,but there was no difference between two groups(P>0.05).
Conclusion: Ganfujian could inhibit the expression of smad2,smad3 and promote the expression of smad7 which could intercepts TGF-β/Samd signal pathway, then delay the process of HF and become an effective therapy for HF.
肝纤维化发生的关键是肝星状细胞(hepatic stellate cell,HSC)的激活及其激活后细胞外基质(extracellular matrixc,ECM)异常表达。从细胞因子及其信号转导角度研究药物的干预机制,有利于促进HF治疗学研究。转化生长因子-β1(transforming growth factor-beta1-1,TGF-β1)是最重要的促肝纤维化细胞因子之一,具有抑制肝细胞增殖、诱导肝细胞凋亡,激活HSC、促进其产生ECM等作用,TGFβ/Smad信号转导通路是TGFβ发挥这些生物效应重要的信号转导通路。
目前临床仍缺乏高效、无明显毒副作用的治疗HF的西药。中医药通过多途径、多环节、多靶点的综合药理学作用在抗HF方面展现出优势,显示了良好的前景。李佃贵教授经过多年的临床实践和基础研究,结合当今疾病模式及疾病谱的变化,提出以“浊毒”立论治疗肝纤维化的理论,并应用化浊解毒调肝法进行治疗,取得较好疗效。依据此理论确立的肝复健方能显著改善HF、慢性肝炎患者临床症状,促进HF指标的恢复;肝复健方能明显改善HF模型大鼠肝功能、抑制肝纤维化大鼠血清HA、LN、Ⅳ-C、PCIII水平,抑制胶原纤维增生等作用。本课题以肝纤维化大鼠模型,以秋水仙碱为对照,观察肝复健方对HF大鼠肝脏TGF-β1及其受体、Smad2/3、Smad4、Smda7的表达情况,探讨其对TGF-β/Smad信号传导通路的影响,旨在对本方抗HF的药效和可能的作用机制作进一步的研究,为其临床应用提供实验依据。本实验分为以下五部分:
第一部分浊毒理论与肝纤维化
目的:以浊毒理论为依据探讨其在肝纤维化治疗中的地位,进而提出新的观点与治疗方法。
方法:温习、回顾了中医理论中浊毒源流,提出浊毒相关为害是肝纤维化的主病机,系统总结了肝纤维化浊毒特性的临床表现、基本治法、用药规律及兼夹证的治疗。
结果:梳理了浊毒之源流,探讨了肝纤维化与浊毒的关系,以及化浊解毒调肝法提出的理论依据,从临床论证了化浊解毒调肝方药治疗肝纤维化的可行性。
结论:浊毒是肝纤维化形成和进展过程中重要的始动因素和关键环节,临床上应用化浊解毒法不仅能改善其症状,还可恢复肝脏生理特性,截断或逆转肝脏病理性改变。
第二部分肝复健方对肝纤维化大鼠肝脏病理组织学的影响
目的:将肝复健方应用于造模成功的HF大鼠,观察肝复健方对HF大鼠一般情况和病理组织学的影响。
方法:健康雄性SD大鼠60只,适应性喂养一周,随机分为正常组(Normal)10只,造模组50只。除正常组外,造模组采用腹腔注射未灭活猪血清法造模,每只大鼠每次注射猪血清0.5 ml,每周2次,共8周。造模成功大鼠分为:模型组,肝复健方小剂量组(以下简称GFJL),肝复健方中剂量组(以下简称GFJM),肝复健方大剂量组(以下简称GFJH),秋水仙碱组,每组均10只。GFJL给予含1.5 g生药/ml水煎剂2ml灌胃;GFJM给予含2.25 g生药/ml水煎剂2ml灌胃;GFJH给予含3.0 g生药/ml水煎剂2ml灌胃;秋水仙碱组给予0.154 g/kg·d灌胃;空白组、模型组均给予等量生理盐水灌胃。各组均灌胃至12周末。造模用药期间观察大鼠一般情况。于12周结束时,断颈处死各组大鼠,留取大鼠肝组织,采用苏木精-伊红染色(HE染色)和Masson染色(胶原纤维特殊染色法)观察肝组织病理形态学改变并进行大鼠肝纤维化病变半定量分析。
结果:
1一般情况观察
肝复健方可明显改善HF大鼠的精神状态、饮食、皮毛色泽,增加其体重。
2肝脏大体形态观察
正常组大鼠肝脏质地柔软,表面光滑。模型组大鼠肝脏质地坚韧,表面粗糙,颜色晦暗,有些可见颗粒状的小结节。秋水仙碱组及肝复健方药物治疗组大鼠肝表面较模型组光滑,质地较柔软。
3肝复健方对肝纤维化大鼠肝组织病理的影响
正常组肝小叶结构完整,肝细胞围绕中央静脉呈放射状排列,无变性坏死,无纤维组织增生。模型组肝小叶结构严重破坏,肝细胞广泛坏死伴炎性细胞浸润,纤维组织大量增生并形成纤维间隔。与模型组比较,各药物治疗组肝小叶结构破坏明显减轻,肝脏胶原纤维增生亦明显减轻,纤维条索疏松变窄。肝细胞水肿好转,变性情况明显改善,炎细胞浸润减少。其中肝复健方高、中剂量组肝脏结构改善较为明显。
4大鼠肝纤维化病变半定量分析
按肝纤维化病变半定量分析判断标准的计分标准,正常组大鼠纤维化程度为0,模型组大鼠纤维化程度为(15.76±0.33),秋水仙碱组大鼠纤维化程度为(5.46±0.20),GFJL大鼠纤维化程度为(11.54±0.36),GFJM大鼠纤维化程度为(9.6±0.16),GFJH大鼠纤维化程度为(5.2±0.12)。与模型组比较,秋水仙碱组、GFJL、GFJM、GFJH大鼠纤维化程度均明显减轻,差异有统计学意义(P<0.05)。
结论:肝复健方能改善HF大鼠一般状况,能显著减轻大鼠肝组织炎症活动度及纤维化程度,体现出较强的保肝、抗HF作用。
第三部分肝复健方对肝纤维化大鼠肝组织TGF-β1的影响
目的:探讨肝复健方对HF大鼠TGF-β1的影响。方法:免疫组织化学法和RT-PCR法分别检测HF大鼠肝组织TGF-β1的表达。
结果:
1肝复健方对大鼠肝组织TGF-β1蛋白表达的影响
正常肝组织中TGF-β1蛋白微弱表达,显色极淡。模型组较正常组TGF-β1阳性信号明显增强;不同剂量肝复健方组TGF-β1蛋白的表达较模型组明显减少(p<0.05),GFJH作用最为明显;秋水仙碱组TGF-β1蛋白的表达较模型组降低(p<0.05)。
2肝复健方对大鼠肝组织TGF-β1mRNA表达的影响
与正常对照组相比,模型组、秋水仙碱组和肝复健方大、中、小剂量组TGF-β1mRNA的表达均明显增强,差异有统计学意义(p<0.05)。与模型对照组相比,秋水仙碱组和肝复健方大、中、小剂量组TGF-β1mRNA表达明显减弱,差异有统计学意义(p<0.05)。且肝复健方大、中剂量组优于秋水仙碱组(p<0.05)。
结论:肝复健方可能通过降低肝组织TGF-β1蛋白及基因的表达而达到抗纤维化的作用。
第四部分肝复健方对肝纤维化大鼠肝组织TβRI、TβRII的影响
目的:探讨肝复健方对HF大鼠TβRI、TβRII表达的影响。方法:免疫组织化学法和RT-PCR法分别检测HF大鼠肝组织TβRI、TβRII的表达。
结果:
1肝复健方对大鼠肝组织TβRI、TβRII蛋白表达的影响
正常对照组肝细胞和间质细胞可见TβRI和TβRII阳性染色,模型组TβRI和TβRII阳性染色显著增强(P<0.05),尤以纤维增生组织和炎性细胞周围多见。与正常组相比,模型组和各治疗组表达明显升高(P<0.05),而与模型组比较,秋水仙碱组和肝复健方各剂量组大鼠肝组织TβRI和TβRII表达则明显降低(P<0.05);各治疗组比较,肝复健方大、中剂量组优于秋水仙碱组(P<0.05)。
2肝复健方对大鼠肝组织TβRI、TβRII mRNA表达的影响
与正常对照组相比,模型对照组、秋水仙碱组和肝复健方大、中、小剂量组TβRI和TβRIImRNA的表达均明显增强,差异有统计学意义(p<0.05)。与模型对照组相比,秋水仙碱组和肝复健方大、中、小剂量组TβRI和TβRIImRNA表达明显减弱,差异有统计学意义(p<0.05)。且肝复健方大、中剂量组优于秋水仙碱组(p<0.05)。
结论:肝复健方能够显著抑制HF大鼠肝组织TβRI、TβRII型受体蛋白及基因的表达,从而抑制HF的发生、发展。
第五部分肝复健方对肝纤维化大鼠肝组织Smads表达的影响
目的:探讨肝复健方对Smad2/3,Smad4,Smad7蛋白表达的影响,结合二、三、四部分,观察其对TGF-β/samd信号通路的影响。
方法:Western blot检测HF大鼠肝组织Smad2/3,Smad4,Smad7的表达。
结果:
1肝复健方对大鼠肝组织Smad2/3、Smad4蛋白表达的影响(1)所有实验组大鼠肝组织中Smad2/3、Smad4的表达量均高于正常对照组(P<0.05);(2)肝复健方各剂量组及秋水仙碱组与模型组相比Smad2/3、Smad4的表达量有显著性降低(P<0.05);(3) GFJL与秋水仙碱组相比Smad2/3、Smad4表达量均无显著性差异(P>0.05);肝复健方中、大剂量组分别与秋水仙碱组相比Smad2/3、Smad4的表达量有显著性降低(P<0.05);(4)GFJH与GFJM相比Smad2/3、Smad4表达量有下降趋势,但无显著性差异(P>0.05)。
2肝复健方对大鼠肝组织Smad7蛋白表达的影响(1)所有实验组大鼠肝组织中Smad7的表达量均低于正常对照组(P<0.05)。(2)肝复健方各剂量组及秋水仙碱组与模型组相比Smad7的表达量显著升高(P<0.05)。(3)GFJL与秋水仙碱组相比Smad7表达量均无显著性差异(P>0.05);肝复健方中、大剂量组分别与秋水仙碱组相比Smad7的表达量显著升高(P<0.05)。(4)GFJH与GFJM相比Smad7表达量有上升趋势,但无显著性差异(P>0.05)。
结论:肝复健方能够抑制受体活化性蛋白smad2和smad3的表达,下调通用性蛋白Smad4的表达,促进抑制性蛋白Smad7的表达,抑制HF大鼠肝脏中TGF-β/smad信号传导通路的激活,从而抑制肝纤维化的发生和发展。
Hepatic fibrosis (HF)is a pathologic process that every kind of disease cause liver injure and inflammation. Its essense is excessive deposition of extracellular matrix(ECM) components in liver,which occurs due to an imbalance between the production and degradation of matrix. It is the hallmark of most chronic liver diseases. The United States 3th liver fibrosis conferences in 2006 indicated that HF is reversible. Professor Hans Popper says:”Who can prevent or delay liver fibrosis, who will be able to cure most chronic liver disease.”
The activation and proliferation of hepatic stellate cell (HSC), which are the major source of ECM, are the crucial event to liver fibrosis. It is advantageous in HF treatment from the cell factor and its signal pathways to study mechanism of drug intervention.Transforming growth factor-beta1-1 (TGF-β1)is one of the most important Hepatic Fibrosis cell factors, can inhibition of hepatocyte proliferation, induce hepatocyte apoptosis, activate HSC,promote formation of ECM.TGF-β1 exerts biological effect mainly through TGF-β/samd signal pathway.
At present clinical still lackes highly effective and no obvious poisonous side effect medicine to treat HF.Traditional Chinese Medicine has seen significant advancement against liver fibrosis. After many years clinical practices and experiment research, combining with current disease pattern and disease spectrum changes,professor Li dian-gui advances the zhuodu theory , applies this theory to treat Hepatic Fibrosis patients ,which obtaining the good curative effect.Ganfujian formula based on zhuodu theory can improve patients’clinical findings, inhibiting inflammatory reaction and fibroplasias to promote the reversion of hepatic fibrosis. The experimental study indicated that,it can obviously reduce HF rat blood serum HA、LN、Ⅳ-C、PCⅢ,reduces the liver inflammation and the fibrosis degree.We still used Hepatic Fibrosis rat’s model, taking the colchicine as the comparison, to determine if Ganfujian formula could inhibit the expression of TGFβ1,TβRI,TβRII,smad2,smad3 and promote the expression of smad7 and then intercepts TGF-β/Samd signal pathway,.This provides scientific evidence for clinic to apply Ganfujian formula in treating cirrhosis. This experiment was separated into five parts:
Part one ZhuoDu theory and Hepatic Fibrosis
Objective: The aim was to study the effect of The ZhuoDu theory in the position of therapy for Hepatic Fibrosis in order to proposes the new viewpoint and the treatment method for HF.
Methods: Reviewed zhuodu’s source and course in the Chinese medicine theory,put forward that the main pathogenesis of Hepatic Fibrosis was zhuodu,and made a systematic summarization on the characteristics of Hepatic Fibrosis,symptoms,general therapies and the treatment of combined syndromes.
Results: We compiled the history of zhuodu ,discussed the relations of Hepatic Fibrosis and zhuodu, searched the treatment of huozhuo jiedu tiaogan theoretical basis,put forward that Hepatic Fibrosis’s main pathogenesis was zhuodu. Clinical curative effect proved that zhuodu theory has a positive position in treatment methods of Hepatic Fibrosis.
Conclusion: Zhuodu closely links with Hepatic Fibrosis in etiology and pathogenesis, also is it’s main pathogenesis.The therapy of huazhuo jiedu used in clinic can not only relieve the symptoms,but also restore the liver physiology characteristic and reversal liver pathology changes.
Part two Effect of Ganfujian formula on liver histopathology in HF rats
Objective: The aim was to observe Ganfujian formula’s effect on rats’ordinary circumstances and change of liver histopathology in HF rats.
Methods:Sixty male Sprague-Dauley rats were selected in this experiment.The animals were randomly divided into normal group(10 rats)and HF model group(50 rats).Besides the normal group, pig’s serum(0.5ml per mouse,twice a week)was established in rats by intraperitoneal injection for eight weeks. The rats of HF model were randomly divided into five groups: the model group,colchicines group,Ganfujian formula low dose group(GFJL), Ganfujian formula of medium dose group(GFJM) and Ganfujian formula of high dose group(GFJH)with 10 rats for each group. After HF models were made successfully,the drugs started be given to the rats according to adult dosage 5,15,20 times,respectively,once daily.The rats were respectively treated with Ganfujian low dose(1.5g crude-drug/ml),Ganfujian middle dose(2.25g crude-drug/ml),Ganfujian high dose(3.0g crude-drug/ml) and colchicine(0.154g/kg·d) intragastrically,the normal group and the model group were given physiological saline by gavage.Each group was given the medicine for 12 weeks. Observed rats’ordinary circumstances.All animals were killed ,the specimens were taken and the degree of hepatic fibrosis was judged by routine haematoxylin-eosin staining and Masson staining. Fibrosis score was calculated by semi-quantitative analysis of liver histopathology.
Results:
1 Rat ordinary circumstances observation
The rat ordinary circumstances observation demonstrated that,The strong 1iver fries by the stasis may obviously improve the HF rat’s state of mind,the diet, the superficial knowledge luster,increases its body weight.
2 Gross findings
Livers of control group were tender and smooth.The ones of model group were hard,coarse and tarnish,with some observable small nodules, whereas the ones of drug groups were smooth and tender.
3 Effect of Ganfujian formula to pathomorphology in hepatic fibrosis rats
The structure of hepatic lobule were integrated hepatic cord radially ranged as the center of navel vein. There was not degeneration and necrosis in liver tissue.There was not collagen proliferation.Compared with normal group,the model control rats had obvious liver inflammation including degeneration,necrosis,fibrosis and collagen proliferation.Pseudolobule proliferation could be seen in individual animal. Compared with model group,in various drug groups,the destructions were lightened,proliferatio ns of collagen fibers were also lightened,fiber cords were loosened and narrowed.Swelling of liver cells and degeneration alleviated,infiltrating cells decreased.These improvements were more significant in high and medium-dose GFJ groups.
4 Semi-quantitative analysis of liver histopathology in HF rats
According to HF semi-quantitative analysis standard,fibrosis score was evaluated on the liver tissue sections performing with HE and Reticulation's stain.The fibrosis score of normal group was 0,model group was 15.76±0.33, colchicines group was 5.46±0.20, GFJL was 11.54±0.36, GFJM was 9.6±0.16, GFJH was 5.2±0.12. Compared with model group, the fibrosis score all decreased in colchicines group, GFJL, GFJM and GFJH(p<0.05).
Conclusion:Ganfujian formula can improve the HF rat’s ordinary circumstances and obviously reduce the rat liver organization inflammation activity and the fibrosis degree,presents the good local constable liver,the anti-HF function.
Part three Effect of Ganfujian formula on TGF-β1 in HF rats
Objective: The aim was to explore Ganfujian formula’s effect on expression of TGF-β1 in HF rats.
Methods: TGFβ1 protein and mRNA expression were determined by using immunohistochemical technique and RT-PCR.
Results:
1 Experimental study on Ganfujian Formula effect on TGF-β1 protein of the hepatic fibrosis rats
Less positive expression of TGF-β1 cell can be seen in the liver tissue of rats form normal group.The expression of TGF-β1 was strongly positive in model group. The cell proportion of TGF-β1 cell expression in the liver tissue of rats form model group were significantly higer than that of the normal group,which were manifested by the unsymmetric brown yellow particulates.The protein level of TGF-β1 of hepatic fibrosis rats could be decreased from Ganfujian group and colchicines group significantly.The effect of GFJH group was better than that others group.
2 Experimental study on Ganfujian formula effect on TGF-β1 mRNA of the hepatic fibrosis rats
Compared with normal group, the level of TGF-β1 mRNA all increased in model group ,Ganfujian group and colchicines group(p<0.05).But the level of TGF-β1 mRNA decreased in Ganfujian group and colchicines group as compared with that in model group(p<0.05),in which,the reduction in medium dose group and high dose group were more than colchicines group(p<0.05).
Conclusion: Ganfujian formula possibly reduce or prevent hepatic fibrosis through decreasing the expression of TGF-β1 protein and mRNA. Part four Effect of Ganfujian formula on TβRI,TβRII in HF rats
Objective: The aim was to explore Ganfujian formula’s effect on expression of TβRI,TβRII in HF rats.
Methods: TβRI,TβRII protein and mRNA expression were determined by using immunohistochemical technique and RT-PCR, respectively.
Results:
1 Expression of TβRI,TβRII protein in liver tissue
TβRI,TβRII protein expressed in hepatocellular and interstitial cells. The expression of TβRI,TβRII protein in model group was stronger than which in normal group(P<0.05), TβRI,TβRII protein especially expressed around fibre hyperplasia and inflammatory cells.Compared with normal group,the expression of TβRI,TβRII protein in other groups was stronger(P<0.05).Compared with model group,the expression of TβRI,TβRII protein in Ganfujian groups and colchicines group was significantly lighter(P<0.05).The expression of TβRI,TβRII protein in GFJH group and GFJM group were lighter than that of colchicines group, there were significantly difference among those groups(P<0.05).
2 Expression of TβRI,TβRII mRNA in liver tissue
Compared with normal group,the expression of TβRI,TβRII mRNA in other groups was stronger(P<0.05).Compared with model group,the expression of TβRI,TβRII mRNA in Ganfujian groups and colchicines group was significantly lighter(P<0.05).The expression of TβRI,TβRII mRNA in GFJH group and GFJM group were lighter than that of colchicines group, there were significantly difference among those groups(P<0.05).
Conclusion: Ganfujian formula can significantly inhibits the expression of TGFβ1 receptors’protein and mRNA.
Part five Effect of Ganfujian formula on Smads in HF rats
Objective: The aim was to explore Ganfujian formula’s effect on expression of Smads’protein in HF rats.Combined with part two,three and four, Our study is to determine if Ganfujian formula intercepts TGF-β/Samd signal pathway.
Methods: Western blotting was used for detecting the protein expression level of Smad2/3,Smad4,Smad7, respectively.
Results:
1 Expression of Smad2/3, Smad4 protein in liver tissue
Compared with normal group,the expression of Smad2/3, Smad4 in other groups was stronger(P<0.05).Compared with model group,the expression of Smad2/3, Smad4 in Ganfujian groups and colchicines group was significantly lighter(P<0.05).Compared with colchicines group, the expression of Smad2/3, Smad4 in GFJM group and GFJH group was significantly lighter(P<0.05),and there was no difference between colchicines group and GFJL group(P>0.05). The expression of Smad2/3, Smad4 in GFJH group was lighter than that of GFJM group,but there was no difference between two groups(P>0.05).
2 Expression of Smad7 protein in liver tissue
Compared with normal group,the expression of Smad7 in other groups was lower(P<0.05).Compared with model group,the expression of Smad7 in Ganfujian groups and colchicines group was significantly stronger(P<0.05).Compared with colchicines group, the expression of Smad7 in GFJM group and GFJH group was significantly stronger(P<0.05),and there was no difference between colchicines group and GFJL group(P>0.05). The expression of Smad7 in GFJH group was stronger than that of GFJM group,but there was no difference between two groups(P>0.05).
Conclusion: Ganfujian could inhibit the expression of smad2,smad3 and promote the expression of smad7 which could intercepts TGF-β/Samd signal pathway, then delay the process of HF and become an effective therapy for HF.
引文
1陈俊荣,陈俊红,侯振江.抗肝纤维化中医治则的临床研究进展[J].世界华人消化杂志,2008,16(3):289-291
2李佃贵,李刚,刘金里,等.李佃贵以“浊毒”立论治疗肝硬化经验[J].陕西中医,2006,27(11):1394-1395
3王珏,裴林,周英,等.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治效果[J].中国临床康复,2006,10 (43):108-111
4常红,李佃贵,张纨,等.肝复健胶囊治疗慢性乙型肝炎肝纤维化患者92例临床观察[J].中成药,2009,31(12):1811-1813
5李佃贵,顾洁,李刚,等.解毒软肝汤对免疫性肝纤维化大鼠整合素α6的影响[J].陕西中医,2007,28(8):1093-1095
6李佃贵,裴林,白文忠,等.肝复健胶囊抗免疫性肝纤维化大鼠的实验研究[J].中成药,2007,29(3):346-348
7王丽,李佃贵,孟宪鑫,等.化浊解毒益气方对肝纤维化大鼠细胞因子的影响[J].中国老年学杂志,2009,29(4):838-840
8夏征农,罗竹风,马飞海等.辞海[M].北京:北京商务印书馆,2000:1124
9印会河.中医基础理论[M].上海:上海科学技术出版社,1984:96
10曹东义.浊毒化与化浊毒.中国中医药报,2010,3.8,学术与临床版
11赵进喜,庞博.中医学“浊”的涵义及其临床意义[J].中医杂志,2009,
50(7):581-584
12谢颖桢,高颖,邹忆怀.试论毒邪致病及证候特征[J].北京中医药大学学报,2001,24(1):11-13
13于智敏.中医学“毒”的病机研究[J].中国中医基础医学杂志,2006,12(12):895-896
14黄琴.温毒概念刍议[J].四川中医,1995,14(12):7-8
15蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎治疗中的应用[J].浙江中医杂志,2002,2:51-52
16刘启泉,李佃贵,张纨,等.慢性胃炎从浊毒论治[J].北京中医药大学学报,2010,33(3):153-155
1杨文卓,曾民德.肝纤维化的发生机制及病理生理[J].国外医学消化系疾病分册,2000,20(4):216-221
2 Glaser SS,Gaudio E,Miller T,Alvaro D,Alpini G.Cholangiocyte proliferation and liver fibrosis[J].Expert reviews in molecular medicine 2009,11:e7
3中华肝脏病学会肝纤维化学组.肝纤维化诊断及疗效评估共识[J].药品评价,2007,4(4):265-266
4梁扩寰,李绍白主编.慢性肝炎-组织学分级,肝脏病学[M].人民卫生出版社,2003年第二版:729-731
5徐叔云.药理实验方法学[M].北京:人民卫生出版社,2002:1351
6王伯云,李玉松,黄高升,等主编.常用的特殊染色方法,病理学技术[M].人民卫生出版社,2000年第一版:142-147
7陈波,何生.肝纤维化动物模型的建立[J].华西医学,2005,20(4):796-797.
8李志钢,杨晋翔,张伟,等.肝纤维化实验动物模型的建立与评价[J].北京中医药大学学报(中医临床版),2009,16(4):43-46.
9 Tsukam oto H,Reidelberger RD,French SW,etal.Long-term cannulationm-odelforblood sam pling and intragastricinfusion in the rat[J].A m JPhysiol,1984,247(3 Pt2):R595-599
10 A riasM,Sauer-Lehnen S,Treptau J,etal.A denoviralexpression of a trans-forming growth factor-beta1 antisense m RN A is effective in preventing liverfibrosisin bile-ductligated rats[J].BM C G astroen-terol,2003,3:29
11吴繁荣,陈飞虎,胡伟,等.鬼针草总黄酮抗大鼠免疫性肝纤维化作用及部分机制研究[J].中国药理学通报,2008,24(6):753-756
12师水生,张辉,尹福忠,等.罗格列酮对免疫性肝纤维化大鼠肝组TGF-β1表达的影响[J].实用肝脏病杂志,2007,10(6):380~383
1 Ulukaya S,Basturk B,Kilic M,Ulukaya E.Cytokine gene polymorphism andpostreperfusion syndrome during orthotopic liver transplantation[J]. Transplantation proceedings,2008,40:1290-1293
2 Herbert DR,Orekov T,Perkins C,Finkelman FD.IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis[J].J Immunol,2008,181:7214-7220
3 Gressner AM,Weiskirchen R. Modem pathogenetic concepts of liver fibrosis suggest stellate cells and TGF beta as major players and therapeutic targets[J].Cell Mol Med,2006,101:76-99
4 Nagashio Y, Ueno H, Imamura M, et al. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice[J].Lab Invest,2004,84:1610-1618
5 Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis[J].Front Biosci,2002,7:d793-807
6 Bedossa P, Paradis V.Transforming growth factor-beta (TGF-beta): a key-ro1e in 1iver fibro genesis[J].J Hepatol, l995,22:37-42
7 Bissell DM,Roulot D,George J.Transforming growth factor beta and the liver[J].Hepatology,Md 2001;34:859-867
8 Border WA,Noble NA.Transforming growth factor beta in tissue fibrosis[J].The New England journal of medicine 1994;331:1286-1292
9 Bonewald LF. Regulation and regulatory of transformating growth factorbeta[J].Crit Rev Eukaryot Gene Expr,1999,9:33-44
10 Liu X,Hu H,Yin JQ.Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis[J].Liver Int.2006,26(1):8-22
11 Hellerbrand C,Stefanovic B,Giordano F.The role of TGF betal in initiating hepatic stellate cell activation in vivo[J].J Hepatol,1999,30:77-87
12刘成海,刘平,胡义梅,等.丹酚酸B盐对转化生长因子刺激肝星状细胞活化与胞内信号转导的作用[J].中华医学杂志,2002, 82(18): 1267-1272
13陈小亮,李俊,邓子煜,等.苦参素对肝纤维化大鼠肝脏TGF-β1的调节作用[J].中国药理学通报,2009,25(6):761-764
14张桂灵,石小枫,冉长清,等.三七总皂甙对抗大鼠免疫性肝纤维化的实验研究[J].第三军医大学学报,2007,29(23):2212-2214
15张国梁,戴敏,许钒,等.软肝饮对免疫性肝纤维化大鼠细胞因子及肝细胞超微结构的影响[J].中医杂志,2006,47(3):219-221
16郑旭锐,叶建红,周新颖,等.加味四逆散对肝纤维化大鼠肝组织转化生长因子、结缔组织生长因子mRNA影响的研究[J].时珍国医国药,2009,20(10):2597-2598
17蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎中的应用[J].浙江中医杂志,2002,2:51-52
18李佃贵,李刚,刘金里,等.李佃贵以“浊毒”立论治疗肝硬化经验[J].陕西中医,2006,27(11):1394-1395
19王珏,裴林,周英,等.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治效果[J].中国临床康复,2006,10 (43):108-111
20李佃贵,李晓荟,李瑞东.解毒软肝汤对免疫性肝纤维化大鼠血清学及组织学的影响[J].陕西中医,2005,26(12):1381-1383
21李佃贵,裴林,白文忠,等.肝复健胶囊抗免疫性肝纤维化大鼠的实验研究[J].中成药,2007,29(3):346-348
22王丽,李佃贵,孟宪鑫,等.化浊解毒益气方对肝纤维化大鼠细胞因子的影响[J].中国老年学杂志,2009,29(4):838-840
23张铁军,陈常青.调节免疫和保肝中药现代研究与应用[M].1版.北京:人民卫生出版社,2007:421.
24汪敏,牟德英,叶劲松,等.田基黄对小鼠实验性肝损伤的保护作用[J].黔南民族医专家报.2002,12,15(4):191-192
25蒋明德,马洪德,钟显飞,等.红景天苷对乙醛刺激的大鼠肝星状细胞激活后功能的影响[J].第四军医大学学报,2005,26(14):1285-1288
26曾维政,吴晓玲,蒋明德,等.红景天苷对肝纤维化大鼠肝组织CBP、Smad基因表达的影响[J].世界华人消化杂志,2005,13(3):341-345
27韦登明,余舰,宋琦,等.绞股蓝总甙防治大鼠肝纤维化的实验研究.时珍国医国药,2002,13(5):257-259
28车建途.治疗肝纤维化的药物[J].中华消化杂志,1993,11:50-51
29高建蓉,张赤志,邵志华,等.鳖甲对肝星状细胞增值影响的研究[J].实用医学杂志,2007,23(11):1618-1620
1 1Kong L,Zhang YG,Wang RQ,Yao SK.The effects of transforming growth factor beta1/Smads signaling pathway changes on the pathogenesis of liver fibrosis[J].Zhonghua Ganzangbing Zazhi,2006,14: 842-844
2 Schnabl B, Kweon YO, Frederick JP,Wang XF,Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation[J].Hepatology,2001,34:89-100
3 Inagaki Y, Mamura M, Kanamaru Y, Greenwel P, Nemoto T, Takehara K, Ten Dijke P, Nakao A. Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen genetranscription in activated hepatic stellate cells[J].J Cell Physiol,2001,187: 117-123
4 De Caesteeker M.The transforming growth factor-beta superfamily of receptors[J].Cytokine Growth Factor Rev,2004,15:1
5 Attisnao L,Wmaa LJ.Singal transduction by theTGF-βsuper family[J].Science,2002,296(5573):1646-1647
6 De Caesteeker M.The transforming growth factor-beta superfamily of receptors[J].Cytokine Growth Factor,2004,15:l-11
7 Finger EC,Lee NY,You HJ,Blobe GC.Endocytosis of the type III transforming growth factor-beta(TGF-beta)receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptordown-regulation[J].The Journal of biological chemistry.2008,283: 34808-34818
8 Blanco FJ,Santibanez JF,Guerrero-Esteo M,Langa C,Vary CP,Bernabeu C.Interaction and functional interplay between endoglin and ALK-1,two components of the endothelial transforming growth factor-beta receptor complex[J].Journal of cellular physiology.2005,204:574-584
9 Gordon KJ,Dong M,Chislock EM,Fields TA,Blobe GC.Loss of type III transforming growth factor beta receptor expression increases motility andinvasiveness associated with epithelial to mesenchymal transitionduring pancreaticcancer progression[J].Carcinogenesis.2008,29:252-262
10 Mitchell H,Choudhury A,Pagano RE,Leof EB.Ligand-dependent and independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11[J].Molecular biology of the cell 2004;15:4166-4178
11宋仕玲,龚作炯,张全荣.金三莪对肝纤维化大鼠TGF-β1及其I、II型受体mRNA与Smad3、Smad7表达的影响[J].中医药学刊,2004, 22(6):1044-1047
1 Derynck R,Zhang YE.Smad-dependent and Smad-independent pathways in TGF-beta family signaling[J].Nature,2003,425(6958):577-584
2 Heldin CH,Miyazono K,Dijke PT,et al.TGF-βsignaling from cellmembrance to nucleus through SMAD proteins[J]. Nature,1997,390(6659):465-471
3吴建新,孟祥军,陈源文,等.Smads信息分子与肝星状细胞的活化[J].胃肠病学和肝病学杂志,2002,11:197-199
4孙校男,娄国强,王先开.γ干扰素对实验性肝纤维化大鼠Smad3mRNA的影响[J].医学研究杂志,2007,12(36):55-57
5 Breitkopf K,Godoy P,Ciuclan L,Singer MV,Dooley S.TGF-β/Smad signaling in the injured liver[J].Z Gastroenterol.2006,(44):57-66
6 Derynck R,ZhangYE.Smad-dependent and Smad-independent pathways in TGF-beta family signaling[J].Nature,2003,425(6958):577-584
7 Liliana Attisano.Signal transduction by the TGF-beta superfamily[J]. Science,2002,296(5573):1646-1647
8 Massague J, Chen YG.Controlling TGF-βsignaling[J].Genes Dev,2000,14:627-644
9 Tahashi Y,Matsuzaki K,Date M,et a1.Differential regulation of TGF-beta signal in hepatic stellate cells between acute andchronic rat liver injury[J]. Hepatology,2002,35:49-61
10 Zuniga JE, Groppe JC, Cui Y, et al. Assembly of TbetaRI:TbetaRII: TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent[J].J Mol Biol, 2005,354:1052-1068.
11黄文林,朱孝峰.信号转导[M].北京:人民卫生出版社,2005,210-212.
12 Datta PK,Moses HL.STRAP and smad7 synergize in the inhibition oftransforming growth factor beta signaling[J].Mol Cell Biol,2000,20(9):3156-3158.
1廖丹,江建宁.肝纤维化形成的机制—信号转导通路TGF-β/smad的作用概论[J].国外医学·流行病学传染病学分册,2004,31(3):170-172
2俞蕾敏,吕宾.TGF-β/smad信号转导通路与肝纤维化的关系[J].国际消化病杂志,2008,28(5):397-400
3 Calabrese F,Valente M,Giacometti C,et al.Parenchymal transforming growth factor beta-1:its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology[J].J Gastroenterol Hepatol,2003,18(11):1302-1808
4 Tsukada S, Parsons CJ, Rippe RA.Mechanisms of liver fibrosis[J].Clin Chim Acta,2006,364:33-60
5 Gao C,Gressner G,Zoremba M,et al.Transforming grow the factor-beta expression inisolated and cultured rat Hepatocytes[J].J Cell physicol, 1996,167(3):394-405
6 Boesen CC,Radaev S,Motyka SA,et al.Structure,2002;10(7):913-919
7 Nagashio Y,Ueno H,Imamura M,et al. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice[J]. Lab Invest,2004,84:1610-1618
8 Cheifetz S,Weatherbee JA,Tsang ML,et al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors[J].Cell,1987,48:409-415
9王连升.TGF-β1信号与肝纤维化[J].国外医学·消化系疾病分册,2004,24(3):142-144
10 SAVAGE C,DAS P,LIFA,et al.Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factorβpathway components[J].Proc Nat Acad SciUSA, 1996,93(2):790-794
11 Massague J,Wotton D.Transcriptional control by the TGF-beta/Smad signaling system[J].EMB J,2000,19:1745-1754
12 WU G, CHEN YG, OZDAMAR B, et al·Structural basis of Smad 2 recognition by the Smad anchor for receptor activation[J].Science, 2000,287(5450): 92-97
13 Zuniga JE, Groppe JC, Cui Y, et al. Assembly of TbetaRI:TbetaRII: TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent[J]. J Mol Biol, 2005,354:1052-1068
14黄文林,朱孝峰.信号转导[M].北京:人民卫生出版社,2005,210-212
15 Datta PK,Moses HL.STRAP and smad7 synergize in the inhibition of transforming growth factor beta signaling[J].Mol Cell Biol, 2000,20(9): 3156-3158
16 Lo RS,Wotton D,Massague J,et al.Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor[J].TGI.F.EMBO J,2001,20(1-2):128-136
17 Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells[J].FASEB J,2003,17:1576-1578
18 Zhang YE.Non-Smad pathways in TGF-beta signaling[J].Cell research 2009,19:128-139
19 Samarakoon R,Higgins PJ.Integration of non-SMAD and SMAD signaling inTGF-beta1-induced plasminogen activator inhibitor type-1 gene expression invascular smooth muscle cells[J].Thrombosis and haemostasis 2008,100:976-983
20 Kretzschmar M,Doody J,Timokhina Z,et al.A mechanism of repression of TGF-beta/Smad signaling by oncogenic Ras[J].Genes Dev, 1999,13(7): 804-816
21 Yakymovych I,Ten Djike P,Heldin CH,et al.Regulation of Smad signaling by Protein kinase C.FASEB J,2001,15(3):553-555
22 Schiller M,Verrecchia F,Mauviel A.Cyclic adenosine3',5'-mono phosphate-elevating agents inhibit transforming growth factor-beta-inducedSMAD3/4-dependent transcription via a protein kinase A-dependent-mechanism[J].Oncogene,2003,22:8881-8890
23 Dupont J, Mc Neilly J, Vaiman A, et al. Activin signaling pathways in ovine pituitary and LbetaT2 gonadotrope cells[J]. Biol Reprod,2003,68:1877-1887
24 Gressner AM,Weiskirchen R,Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis[J].Front Biosci,2002,7:d793-807
25曾维政,吴晓玲,蒋明德,等.复方红景天对大鼠肝组织转化生长因子-β1mRNA表达的影响[J].中国中西医结合消化杂志,2002,10(3):138-141
26宋仕玲,龚作炯,张全荣,等.金三莪对实验性肝纤维化大鼠TGF-β1、Smad3、Smad7及CTGF表达的影响[J].天津中医药, 2004, 21(1):62-64
27宋仕玲,龚作炯,张全荣.金三莪术肝纤维化大鼠TGF-β及其I, II型受体mRNA与Smad3、Smad7表达的影响.中医药学刊,2004,22:1044-1047
28王晓柠,胡义扬,刘成海,等.丹酚酸B盐对二甲基亚硝胺诱导的肝纤维化大鼠肝脏转化生长因子-β1及其受体蛋白表达的影响[J].中西医结合学报, 2005, 3(4):286-289
29张国梁,戴敏,许钒,等.软肝饮对免疫性肝纤维化大鼠细胞因子及肝细胞超微结构的影响[J].中医杂志,2006,47(3):219-221
30 AriasM, Lahme B, Van de Leur E,et al.A denoviral delivery of an antisense RNA complementary to the 3 ' coding sequence of transforming growth factor-betal inhibits fibrogenic activities of hepatic stellate cells[J].Cell Growth Differ, 2002, 13 (6): 265-273
31汪玲,胡国龄,谭德明,等. TGF-β1II型受体部分基因表达质粒对实验性大鼠肝纤维化的影响.中华传染病杂志,2002,20:168-171
32蒋炜,王吉耀,杨长青,等.反义转化生长因子βII型受体表达质粒对实验性肝纤维化的影响[J].中华肝脏病杂志,2004,12:137-140
33 Zheng S, Chen A. Curcum in suppresses the expression of extracel lu lar matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor[J].Am J Physiol Gastrointest Liver Physiol. 2006,290:883-893
34 Ueno H, Sakamoto T, Nakamura T, et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats[J]. Hum Gene Ther, 2000, 11:33~42
35 Joanne Ho,Hui Chen,Jean-JacquesLebrun.Novel dominant negative Smad antagonists to TGFβsignaling [J].Cellular Signalling,2007,19(7):1565-1574
36 Schnabl B, Kweon YO, Frederick JP, et al. The role of Smad3 inmediating mouse hepatic stellate cell activation [J]. Hepatology,2001, 34(1):89-100
37 Xu Xb,Leng Xs,He Zp,et al.Inhibitory effect of retroviral vectorcontaining anti-sense Smad4 gene on Ito cell line,LI90[J].Chin Med J(Eng1),2004,117 (8):1170-1177
38 Dooley S,Hanzavi J,Breitkopr K,et al.Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats[J].Gastroenterology,2003,125(1):178-191
1刘成海,刘平,胡义扬,等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术-中医药现代化
创新论坛,2007,9(2):112-119
2丁宁.肝纤维化形成机制的研究进展[J].临床肝胆病杂志,2009,25(1): 75-77
3高春芳,陆伦根.纤维化疾病的基础和临床[M].上海,上海科学技术出版社,2004,5月第一版:337
4 Beljaars L, Meijer DK, Poelstra K.Targeting hepatic stellate cells for cell-specific treatment on liver fibrosis [J].Front Biosci,2002,7:214-222
5 Hung KS, Lee TH, Chou WY, et al. Interleukin-10gene therapyreverses thioacetamide liver fibrosis in mice[J].Biochem Bioph Res Co,2005, 336:324-331
6 Tu CT,Guo JS,Wang M, et al.Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury[J].JGastroen Hepatol,2007,22:877-884
7 CAI W M.Some reseach progression of hepatic fibrosis[J].Chinese Clinic Hepatol, 2006, 2(3): 167-170
8 Iseri SO,Sener G,Saglam B,et al.Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats[J].RegulPeptides,2008,146:73-79
9白艳锋,尤红.肝纤维化形成中MMPs/TIMPs的动态变化及治疗进展[J].肝脏,2009,14(2):162-164
10 FRIEDMAN S L,ROCKEY D C,BISSELL D M.Hepati fibrosis 2006:Report of the third AASLD single tropic research conference[J].Hepotlolgy,2007,45(1): 242-249
11 Du SL,Pan H, Lu WY,et al.Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats[J].J Pharmacol Exp Ther,2007,322:560-568
12 WASMUTHH E,TRAUTWEIN C CB1 Cannabinoid receptor antagonism:A new strategy for the treatment of liver fibrosis[J].2007,45(2):543-544
13陈诗书.基因治疗[M]//陈诗书,汤雪明.医学细胞与分子生物学.2版.北京:科学出版社,2004:844-876
14 Wei J,Yang CQ,Liu WB,et al.Blockage of transforming growth factor receptors prevents progression of pig serum-induced rat liver fibrosis[J].J World Gastroenterol,2004,10:1634-1638
15薛秀兰,林菊生,宋宇虎,等.靶向leptin基因的SiRNA对鼠肝星状细胞生物学特性的影响[J].华中科技大学学报(医学版),2006,35:331-335
16 Hu YB,Li DG,Lu HM.Modified synthetic SiRNA targeting tissue inhibitor of metalloproteinase-I inhibits hepatic fibrogenesis in rats[J].J Gene Med,2007,9:217-229
17 Li GM,Xie Q,Shi Y,et al. Small interfering RNA targeting connective tissue growth factor prevents rat liver fibrosis[J].Chin J Dig, 2005,25: 336-339
18苗韫晗.复方鳖甲软肝片治疗40例肝纤维化临床观察[J].当代医学,2009,15(22):140
19李丰衣,孙劲晖,田德禄,等.复方鳖甲软肝片抑制大鼠酒精性肝纤维化作用机制研究[J].中国中医药信息杂志,2009 ,16( 05):26-28
20蔺武,刘心娟,魏南,等.复方鳖甲软肝片抗肝纤维化疗效的系统评价[J].胃肠病学和肝病学杂志,2007,16(1):69-72
21王海燕,朱跃科,申凤俊,等.复方861对DMN损伤性大鼠肝肝纤维中肝脏MMP-2表达的影响[J].中国现代医药杂志,2007,9(4):31
22王宝恩,赵洪涛,王泰玲,等.复方861对肝炎肝纤维化疗效的病理组织学分析[J].中华肝脏病杂志,1997, 5(2)77-78
23蔡卫民.抗肝纤维化药物研究新进展[J].中国药学杂志,2008, 43(3):161-164
24赵长青,吴艺青,徐列明.扶正化瘀胶囊抗肝纤维化的临床疗效和作用机制[J].中西医结合学报,2006,4(5): 467-472
25秦莉,陈欣.扶正化瘀胶囊对慢性乙型肝炎肝纤维化的影响[J].新中医,2008, 40(11):35-36
26徐列明.扶正化瘀胶囊的后续研究[J].药品评价,2008,5(5):198-200,225
27解毒软肝汤对免疫性肝纤维化大鼠血清学及组织学的影响[J].陕西中医,2005,26(12):1381-1383
28李佃贵,裴林,白文忠,等.肝复健胶囊抗免疫性肝纤维化大鼠的实验研究[J].中成药,2007,29(3):346-348
29王珏,裴林,周英,王恩江,郎新宇,李佃贵.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治效果[J].中国临床康复,2006, 10(43):108-111
30林寿宁,朱永苹,雷力民,等.壮肝逐瘀颗粒抗肝纤维化的实验研究[J].广西中医药,2009,32(1):56-58
31梁润英,路嵘.鳖甲抗纤方抗肝纤维化作用的实验[J].中国中医药科技,2004,11(1):16-18
32任映,宋崇顺,尹军祥,等.加味鳖甲煎丸对四氯化碳所致肝纤维化大鼠的治疗作用[J].北京中医药大学学报,2007,30(1):48-50
33高建蓉,张赤志,邵志华,等.鳖甲对肝星状细胞增值影响的研究[J].实用医学杂志,2007,23(11):1618-1620
34陈几香,张建国,张莉,刘京渤.绞股蓝总皂普保肝作用实验研究[J].中国药业,2007,16(13):7-8
35韦登明,余舰,宋琦,等.绞股蓝总苷防治大鼠肝纤维化的实验研究[J].时珍国医国药,2002,13(5):9,257
36吴晓玲,曾维政,蒋明德等.红景天甙对肝纤维化大鼠Samds基因表达的影响[J].第四军医大学学报,2005,26(10):923-926
37吴晓玲,曾维政,蒋明德等.红景天甙对肝纤维化大鼠肝组织ROCK表达的影响[J].世界华人消化杂志,2009,17(8):765-769
38姜兆金,雷明君.甘利欣联合复方丹参治疗慢性乙型肝炎肝纤维化的临床研究[J].肝脏,2007,12(2):159-160
39李校天,杨书良,王军民,等.丹参对肝星状细胞丝裂原活化蛋白激酶通路的抑制作用[J].解放军医学杂志,2006,31(1):22-24
40刘丽,姜慧卿,张晓岚,等.丹参单体IH764-3通过下调H2O2刺激的肝星状细胞FAK水平影响MMP-13和TIMP-1的表达[J].中国应用生理学杂志,2007,23(4):482-486
41吴有莲.苦参碱抗肝纤维化临床研究[J].中药材,2004,27(2):153-154
42卢清,张清波,张继明,等.氧化苦参碱对大鼠肝星状细胞旁分泌活化途径的抑制作用[J].肝脏,2004,9(1):31-33
43陈小亮,李俊,邓子煜.苦参素对肝纤维化大鼠肝脏TGF-β1的调节作用[J].中国药理学通报,2009,25(6):761-764
44杨晴,颜迎春.去纤软肝胶囊治疗乙型肝炎肝纤维化38例[J].中西医结合肝病杂志, 2001,11(5) :300.
45徐列明,刘成,刘平.扁桃苷对大鼠贮脂细胞增殖和产生胶原的影响[J].新消化病学杂志.2007.5(2):84-85
46张晓平,陈建明,强世平,等.山桃仁水煎提取物对肝纤维化小鼠血清I、III型前胶原的降解作用[J].福建中医药,2002,33(4):36
47蔡瑜,沈锡中,王吉耀.甘草酸对肝纤维化基因表达的影响[J].中华医学杂志,2003,83:1122-1125
48董玲,孙剑勇,方国汀,等.甘草酸对转化因子β1刺激肝星状细胞信号转导的作用[J].中华肝脏病杂志,2005,13:828-831
49周朝晖,蔡瑜,沈锡中,等.甘草酸对CCL4肝纤维化大鼠肝组织Smad7免疫组织化学法表达的影响[J].中国临床医学,2006,2:67-69
50陈在忠,王红.川芎嗪抗肝纤维化作用的实验研究[J].中西医结合肝病杂志,2007,7(3):156-158
51华海婴,李艳瑛,戈士文.川芎嗪抗大鼠免疫损伤性肝纤维化作用及机制研究[J].中药药理与临床,2007,23(5):60
52 Zhang FL,Wei YJ,Zhu J, et al. Simultaneous quantitation of three major triterpenoid glycosides in Centella asiatica extracts by high performance liquid chromatography with evaporative light scattering detection[J]. Biomed Chromatogr, 2008, 22(2): 119-124
53杨光,谭家驹,何瑞华等.积雪草酸阻断大鼠肝纤维化的实验研究[J].中国中医基础医学杂志,2009,15(7):540-542
54樊冬梅,任宝琦,刘凤斌,等.中西医结合方案对慢性乙肝抗肝纤维化的临床研究[J].长春中医药大学学报, 2008, 24 (3): 288-289
55黎琮毅,涂燕云,邱琦.中西医结合治疗慢性乙型肝炎32例及对肝纤维化影响[J].福建中医药,2009,40(5):7-8
56梁芳,李长秦,李环.肝康颗粒联合干扰素治疗乙型肝炎肝纤维化临床观察[J].山西中医,2009,25(11):31-33
2李佃贵,李刚,刘金里,等.李佃贵以“浊毒”立论治疗肝硬化经验[J].陕西中医,2006,27(11):1394-1395
3王珏,裴林,周英,等.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治效果[J].中国临床康复,2006,10 (43):108-111
4常红,李佃贵,张纨,等.肝复健胶囊治疗慢性乙型肝炎肝纤维化患者92例临床观察[J].中成药,2009,31(12):1811-1813
5李佃贵,顾洁,李刚,等.解毒软肝汤对免疫性肝纤维化大鼠整合素α6的影响[J].陕西中医,2007,28(8):1093-1095
6李佃贵,裴林,白文忠,等.肝复健胶囊抗免疫性肝纤维化大鼠的实验研究[J].中成药,2007,29(3):346-348
7王丽,李佃贵,孟宪鑫,等.化浊解毒益气方对肝纤维化大鼠细胞因子的影响[J].中国老年学杂志,2009,29(4):838-840
8夏征农,罗竹风,马飞海等.辞海[M].北京:北京商务印书馆,2000:1124
9印会河.中医基础理论[M].上海:上海科学技术出版社,1984:96
10曹东义.浊毒化与化浊毒.中国中医药报,2010,3.8,学术与临床版
11赵进喜,庞博.中医学“浊”的涵义及其临床意义[J].中医杂志,2009,
50(7):581-584
12谢颖桢,高颖,邹忆怀.试论毒邪致病及证候特征[J].北京中医药大学学报,2001,24(1):11-13
13于智敏.中医学“毒”的病机研究[J].中国中医基础医学杂志,2006,12(12):895-896
14黄琴.温毒概念刍议[J].四川中医,1995,14(12):7-8
15蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎治疗中的应用[J].浙江中医杂志,2002,2:51-52
16刘启泉,李佃贵,张纨,等.慢性胃炎从浊毒论治[J].北京中医药大学学报,2010,33(3):153-155
1杨文卓,曾民德.肝纤维化的发生机制及病理生理[J].国外医学消化系疾病分册,2000,20(4):216-221
2 Glaser SS,Gaudio E,Miller T,Alvaro D,Alpini G.Cholangiocyte proliferation and liver fibrosis[J].Expert reviews in molecular medicine 2009,11:e7
3中华肝脏病学会肝纤维化学组.肝纤维化诊断及疗效评估共识[J].药品评价,2007,4(4):265-266
4梁扩寰,李绍白主编.慢性肝炎-组织学分级,肝脏病学[M].人民卫生出版社,2003年第二版:729-731
5徐叔云.药理实验方法学[M].北京:人民卫生出版社,2002:1351
6王伯云,李玉松,黄高升,等主编.常用的特殊染色方法,病理学技术[M].人民卫生出版社,2000年第一版:142-147
7陈波,何生.肝纤维化动物模型的建立[J].华西医学,2005,20(4):796-797.
8李志钢,杨晋翔,张伟,等.肝纤维化实验动物模型的建立与评价[J].北京中医药大学学报(中医临床版),2009,16(4):43-46.
9 Tsukam oto H,Reidelberger RD,French SW,etal.Long-term cannulationm-odelforblood sam pling and intragastricinfusion in the rat[J].A m JPhysiol,1984,247(3 Pt2):R595-599
10 A riasM,Sauer-Lehnen S,Treptau J,etal.A denoviralexpression of a trans-forming growth factor-beta1 antisense m RN A is effective in preventing liverfibrosisin bile-ductligated rats[J].BM C G astroen-terol,2003,3:29
11吴繁荣,陈飞虎,胡伟,等.鬼针草总黄酮抗大鼠免疫性肝纤维化作用及部分机制研究[J].中国药理学通报,2008,24(6):753-756
12师水生,张辉,尹福忠,等.罗格列酮对免疫性肝纤维化大鼠肝组TGF-β1表达的影响[J].实用肝脏病杂志,2007,10(6):380~383
1 Ulukaya S,Basturk B,Kilic M,Ulukaya E.Cytokine gene polymorphism andpostreperfusion syndrome during orthotopic liver transplantation[J]. Transplantation proceedings,2008,40:1290-1293
2 Herbert DR,Orekov T,Perkins C,Finkelman FD.IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis[J].J Immunol,2008,181:7214-7220
3 Gressner AM,Weiskirchen R. Modem pathogenetic concepts of liver fibrosis suggest stellate cells and TGF beta as major players and therapeutic targets[J].Cell Mol Med,2006,101:76-99
4 Nagashio Y, Ueno H, Imamura M, et al. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice[J].Lab Invest,2004,84:1610-1618
5 Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis[J].Front Biosci,2002,7:d793-807
6 Bedossa P, Paradis V.Transforming growth factor-beta (TGF-beta): a key-ro1e in 1iver fibro genesis[J].J Hepatol, l995,22:37-42
7 Bissell DM,Roulot D,George J.Transforming growth factor beta and the liver[J].Hepatology,Md 2001;34:859-867
8 Border WA,Noble NA.Transforming growth factor beta in tissue fibrosis[J].The New England journal of medicine 1994;331:1286-1292
9 Bonewald LF. Regulation and regulatory of transformating growth factorbeta[J].Crit Rev Eukaryot Gene Expr,1999,9:33-44
10 Liu X,Hu H,Yin JQ.Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis[J].Liver Int.2006,26(1):8-22
11 Hellerbrand C,Stefanovic B,Giordano F.The role of TGF betal in initiating hepatic stellate cell activation in vivo[J].J Hepatol,1999,30:77-87
12刘成海,刘平,胡义梅,等.丹酚酸B盐对转化生长因子刺激肝星状细胞活化与胞内信号转导的作用[J].中华医学杂志,2002, 82(18): 1267-1272
13陈小亮,李俊,邓子煜,等.苦参素对肝纤维化大鼠肝脏TGF-β1的调节作用[J].中国药理学通报,2009,25(6):761-764
14张桂灵,石小枫,冉长清,等.三七总皂甙对抗大鼠免疫性肝纤维化的实验研究[J].第三军医大学学报,2007,29(23):2212-2214
15张国梁,戴敏,许钒,等.软肝饮对免疫性肝纤维化大鼠细胞因子及肝细胞超微结构的影响[J].中医杂志,2006,47(3):219-221
16郑旭锐,叶建红,周新颖,等.加味四逆散对肝纤维化大鼠肝组织转化生长因子、结缔组织生长因子mRNA影响的研究[J].时珍国医国药,2009,20(10):2597-2598
17蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎中的应用[J].浙江中医杂志,2002,2:51-52
18李佃贵,李刚,刘金里,等.李佃贵以“浊毒”立论治疗肝硬化经验[J].陕西中医,2006,27(11):1394-1395
19王珏,裴林,周英,等.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治效果[J].中国临床康复,2006,10 (43):108-111
20李佃贵,李晓荟,李瑞东.解毒软肝汤对免疫性肝纤维化大鼠血清学及组织学的影响[J].陕西中医,2005,26(12):1381-1383
21李佃贵,裴林,白文忠,等.肝复健胶囊抗免疫性肝纤维化大鼠的实验研究[J].中成药,2007,29(3):346-348
22王丽,李佃贵,孟宪鑫,等.化浊解毒益气方对肝纤维化大鼠细胞因子的影响[J].中国老年学杂志,2009,29(4):838-840
23张铁军,陈常青.调节免疫和保肝中药现代研究与应用[M].1版.北京:人民卫生出版社,2007:421.
24汪敏,牟德英,叶劲松,等.田基黄对小鼠实验性肝损伤的保护作用[J].黔南民族医专家报.2002,12,15(4):191-192
25蒋明德,马洪德,钟显飞,等.红景天苷对乙醛刺激的大鼠肝星状细胞激活后功能的影响[J].第四军医大学学报,2005,26(14):1285-1288
26曾维政,吴晓玲,蒋明德,等.红景天苷对肝纤维化大鼠肝组织CBP、Smad基因表达的影响[J].世界华人消化杂志,2005,13(3):341-345
27韦登明,余舰,宋琦,等.绞股蓝总甙防治大鼠肝纤维化的实验研究.时珍国医国药,2002,13(5):257-259
28车建途.治疗肝纤维化的药物[J].中华消化杂志,1993,11:50-51
29高建蓉,张赤志,邵志华,等.鳖甲对肝星状细胞增值影响的研究[J].实用医学杂志,2007,23(11):1618-1620
1 1Kong L,Zhang YG,Wang RQ,Yao SK.The effects of transforming growth factor beta1/Smads signaling pathway changes on the pathogenesis of liver fibrosis[J].Zhonghua Ganzangbing Zazhi,2006,14: 842-844
2 Schnabl B, Kweon YO, Frederick JP,Wang XF,Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation[J].Hepatology,2001,34:89-100
3 Inagaki Y, Mamura M, Kanamaru Y, Greenwel P, Nemoto T, Takehara K, Ten Dijke P, Nakao A. Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen genetranscription in activated hepatic stellate cells[J].J Cell Physiol,2001,187: 117-123
4 De Caesteeker M.The transforming growth factor-beta superfamily of receptors[J].Cytokine Growth Factor Rev,2004,15:1
5 Attisnao L,Wmaa LJ.Singal transduction by theTGF-βsuper family[J].Science,2002,296(5573):1646-1647
6 De Caesteeker M.The transforming growth factor-beta superfamily of receptors[J].Cytokine Growth Factor,2004,15:l-11
7 Finger EC,Lee NY,You HJ,Blobe GC.Endocytosis of the type III transforming growth factor-beta(TGF-beta)receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptordown-regulation[J].The Journal of biological chemistry.2008,283: 34808-34818
8 Blanco FJ,Santibanez JF,Guerrero-Esteo M,Langa C,Vary CP,Bernabeu C.Interaction and functional interplay between endoglin and ALK-1,two components of the endothelial transforming growth factor-beta receptor complex[J].Journal of cellular physiology.2005,204:574-584
9 Gordon KJ,Dong M,Chislock EM,Fields TA,Blobe GC.Loss of type III transforming growth factor beta receptor expression increases motility andinvasiveness associated with epithelial to mesenchymal transitionduring pancreaticcancer progression[J].Carcinogenesis.2008,29:252-262
10 Mitchell H,Choudhury A,Pagano RE,Leof EB.Ligand-dependent and independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11[J].Molecular biology of the cell 2004;15:4166-4178
11宋仕玲,龚作炯,张全荣.金三莪对肝纤维化大鼠TGF-β1及其I、II型受体mRNA与Smad3、Smad7表达的影响[J].中医药学刊,2004, 22(6):1044-1047
1 Derynck R,Zhang YE.Smad-dependent and Smad-independent pathways in TGF-beta family signaling[J].Nature,2003,425(6958):577-584
2 Heldin CH,Miyazono K,Dijke PT,et al.TGF-βsignaling from cellmembrance to nucleus through SMAD proteins[J]. Nature,1997,390(6659):465-471
3吴建新,孟祥军,陈源文,等.Smads信息分子与肝星状细胞的活化[J].胃肠病学和肝病学杂志,2002,11:197-199
4孙校男,娄国强,王先开.γ干扰素对实验性肝纤维化大鼠Smad3mRNA的影响[J].医学研究杂志,2007,12(36):55-57
5 Breitkopf K,Godoy P,Ciuclan L,Singer MV,Dooley S.TGF-β/Smad signaling in the injured liver[J].Z Gastroenterol.2006,(44):57-66
6 Derynck R,ZhangYE.Smad-dependent and Smad-independent pathways in TGF-beta family signaling[J].Nature,2003,425(6958):577-584
7 Liliana Attisano.Signal transduction by the TGF-beta superfamily[J]. Science,2002,296(5573):1646-1647
8 Massague J, Chen YG.Controlling TGF-βsignaling[J].Genes Dev,2000,14:627-644
9 Tahashi Y,Matsuzaki K,Date M,et a1.Differential regulation of TGF-beta signal in hepatic stellate cells between acute andchronic rat liver injury[J]. Hepatology,2002,35:49-61
10 Zuniga JE, Groppe JC, Cui Y, et al. Assembly of TbetaRI:TbetaRII: TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent[J].J Mol Biol, 2005,354:1052-1068.
11黄文林,朱孝峰.信号转导[M].北京:人民卫生出版社,2005,210-212.
12 Datta PK,Moses HL.STRAP and smad7 synergize in the inhibition oftransforming growth factor beta signaling[J].Mol Cell Biol,2000,20(9):3156-3158.
1廖丹,江建宁.肝纤维化形成的机制—信号转导通路TGF-β/smad的作用概论[J].国外医学·流行病学传染病学分册,2004,31(3):170-172
2俞蕾敏,吕宾.TGF-β/smad信号转导通路与肝纤维化的关系[J].国际消化病杂志,2008,28(5):397-400
3 Calabrese F,Valente M,Giacometti C,et al.Parenchymal transforming growth factor beta-1:its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology[J].J Gastroenterol Hepatol,2003,18(11):1302-1808
4 Tsukada S, Parsons CJ, Rippe RA.Mechanisms of liver fibrosis[J].Clin Chim Acta,2006,364:33-60
5 Gao C,Gressner G,Zoremba M,et al.Transforming grow the factor-beta expression inisolated and cultured rat Hepatocytes[J].J Cell physicol, 1996,167(3):394-405
6 Boesen CC,Radaev S,Motyka SA,et al.Structure,2002;10(7):913-919
7 Nagashio Y,Ueno H,Imamura M,et al. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice[J]. Lab Invest,2004,84:1610-1618
8 Cheifetz S,Weatherbee JA,Tsang ML,et al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors[J].Cell,1987,48:409-415
9王连升.TGF-β1信号与肝纤维化[J].国外医学·消化系疾病分册,2004,24(3):142-144
10 SAVAGE C,DAS P,LIFA,et al.Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factorβpathway components[J].Proc Nat Acad SciUSA, 1996,93(2):790-794
11 Massague J,Wotton D.Transcriptional control by the TGF-beta/Smad signaling system[J].EMB J,2000,19:1745-1754
12 WU G, CHEN YG, OZDAMAR B, et al·Structural basis of Smad 2 recognition by the Smad anchor for receptor activation[J].Science, 2000,287(5450): 92-97
13 Zuniga JE, Groppe JC, Cui Y, et al. Assembly of TbetaRI:TbetaRII: TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent[J]. J Mol Biol, 2005,354:1052-1068
14黄文林,朱孝峰.信号转导[M].北京:人民卫生出版社,2005,210-212
15 Datta PK,Moses HL.STRAP and smad7 synergize in the inhibition of transforming growth factor beta signaling[J].Mol Cell Biol, 2000,20(9): 3156-3158
16 Lo RS,Wotton D,Massague J,et al.Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor[J].TGI.F.EMBO J,2001,20(1-2):128-136
17 Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells[J].FASEB J,2003,17:1576-1578
18 Zhang YE.Non-Smad pathways in TGF-beta signaling[J].Cell research 2009,19:128-139
19 Samarakoon R,Higgins PJ.Integration of non-SMAD and SMAD signaling inTGF-beta1-induced plasminogen activator inhibitor type-1 gene expression invascular smooth muscle cells[J].Thrombosis and haemostasis 2008,100:976-983
20 Kretzschmar M,Doody J,Timokhina Z,et al.A mechanism of repression of TGF-beta/Smad signaling by oncogenic Ras[J].Genes Dev, 1999,13(7): 804-816
21 Yakymovych I,Ten Djike P,Heldin CH,et al.Regulation of Smad signaling by Protein kinase C.FASEB J,2001,15(3):553-555
22 Schiller M,Verrecchia F,Mauviel A.Cyclic adenosine3',5'-mono phosphate-elevating agents inhibit transforming growth factor-beta-inducedSMAD3/4-dependent transcription via a protein kinase A-dependent-mechanism[J].Oncogene,2003,22:8881-8890
23 Dupont J, Mc Neilly J, Vaiman A, et al. Activin signaling pathways in ovine pituitary and LbetaT2 gonadotrope cells[J]. Biol Reprod,2003,68:1877-1887
24 Gressner AM,Weiskirchen R,Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis[J].Front Biosci,2002,7:d793-807
25曾维政,吴晓玲,蒋明德,等.复方红景天对大鼠肝组织转化生长因子-β1mRNA表达的影响[J].中国中西医结合消化杂志,2002,10(3):138-141
26宋仕玲,龚作炯,张全荣,等.金三莪对实验性肝纤维化大鼠TGF-β1、Smad3、Smad7及CTGF表达的影响[J].天津中医药, 2004, 21(1):62-64
27宋仕玲,龚作炯,张全荣.金三莪术肝纤维化大鼠TGF-β及其I, II型受体mRNA与Smad3、Smad7表达的影响.中医药学刊,2004,22:1044-1047
28王晓柠,胡义扬,刘成海,等.丹酚酸B盐对二甲基亚硝胺诱导的肝纤维化大鼠肝脏转化生长因子-β1及其受体蛋白表达的影响[J].中西医结合学报, 2005, 3(4):286-289
29张国梁,戴敏,许钒,等.软肝饮对免疫性肝纤维化大鼠细胞因子及肝细胞超微结构的影响[J].中医杂志,2006,47(3):219-221
30 AriasM, Lahme B, Van de Leur E,et al.A denoviral delivery of an antisense RNA complementary to the 3 ' coding sequence of transforming growth factor-betal inhibits fibrogenic activities of hepatic stellate cells[J].Cell Growth Differ, 2002, 13 (6): 265-273
31汪玲,胡国龄,谭德明,等. TGF-β1II型受体部分基因表达质粒对实验性大鼠肝纤维化的影响.中华传染病杂志,2002,20:168-171
32蒋炜,王吉耀,杨长青,等.反义转化生长因子βII型受体表达质粒对实验性肝纤维化的影响[J].中华肝脏病杂志,2004,12:137-140
33 Zheng S, Chen A. Curcum in suppresses the expression of extracel lu lar matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor[J].Am J Physiol Gastrointest Liver Physiol. 2006,290:883-893
34 Ueno H, Sakamoto T, Nakamura T, et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats[J]. Hum Gene Ther, 2000, 11:33~42
35 Joanne Ho,Hui Chen,Jean-JacquesLebrun.Novel dominant negative Smad antagonists to TGFβsignaling [J].Cellular Signalling,2007,19(7):1565-1574
36 Schnabl B, Kweon YO, Frederick JP, et al. The role of Smad3 inmediating mouse hepatic stellate cell activation [J]. Hepatology,2001, 34(1):89-100
37 Xu Xb,Leng Xs,He Zp,et al.Inhibitory effect of retroviral vectorcontaining anti-sense Smad4 gene on Ito cell line,LI90[J].Chin Med J(Eng1),2004,117 (8):1170-1177
38 Dooley S,Hanzavi J,Breitkopr K,et al.Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats[J].Gastroenterology,2003,125(1):178-191
1刘成海,刘平,胡义扬,等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术-中医药现代化
创新论坛,2007,9(2):112-119
2丁宁.肝纤维化形成机制的研究进展[J].临床肝胆病杂志,2009,25(1): 75-77
3高春芳,陆伦根.纤维化疾病的基础和临床[M].上海,上海科学技术出版社,2004,5月第一版:337
4 Beljaars L, Meijer DK, Poelstra K.Targeting hepatic stellate cells for cell-specific treatment on liver fibrosis [J].Front Biosci,2002,7:214-222
5 Hung KS, Lee TH, Chou WY, et al. Interleukin-10gene therapyreverses thioacetamide liver fibrosis in mice[J].Biochem Bioph Res Co,2005, 336:324-331
6 Tu CT,Guo JS,Wang M, et al.Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury[J].JGastroen Hepatol,2007,22:877-884
7 CAI W M.Some reseach progression of hepatic fibrosis[J].Chinese Clinic Hepatol, 2006, 2(3): 167-170
8 Iseri SO,Sener G,Saglam B,et al.Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats[J].RegulPeptides,2008,146:73-79
9白艳锋,尤红.肝纤维化形成中MMPs/TIMPs的动态变化及治疗进展[J].肝脏,2009,14(2):162-164
10 FRIEDMAN S L,ROCKEY D C,BISSELL D M.Hepati fibrosis 2006:Report of the third AASLD single tropic research conference[J].Hepotlolgy,2007,45(1): 242-249
11 Du SL,Pan H, Lu WY,et al.Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats[J].J Pharmacol Exp Ther,2007,322:560-568
12 WASMUTHH E,TRAUTWEIN C CB1 Cannabinoid receptor antagonism:A new strategy for the treatment of liver fibrosis[J].2007,45(2):543-544
13陈诗书.基因治疗[M]//陈诗书,汤雪明.医学细胞与分子生物学.2版.北京:科学出版社,2004:844-876
14 Wei J,Yang CQ,Liu WB,et al.Blockage of transforming growth factor receptors prevents progression of pig serum-induced rat liver fibrosis[J].J World Gastroenterol,2004,10:1634-1638
15薛秀兰,林菊生,宋宇虎,等.靶向leptin基因的SiRNA对鼠肝星状细胞生物学特性的影响[J].华中科技大学学报(医学版),2006,35:331-335
16 Hu YB,Li DG,Lu HM.Modified synthetic SiRNA targeting tissue inhibitor of metalloproteinase-I inhibits hepatic fibrogenesis in rats[J].J Gene Med,2007,9:217-229
17 Li GM,Xie Q,Shi Y,et al. Small interfering RNA targeting connective tissue growth factor prevents rat liver fibrosis[J].Chin J Dig, 2005,25: 336-339
18苗韫晗.复方鳖甲软肝片治疗40例肝纤维化临床观察[J].当代医学,2009,15(22):140
19李丰衣,孙劲晖,田德禄,等.复方鳖甲软肝片抑制大鼠酒精性肝纤维化作用机制研究[J].中国中医药信息杂志,2009 ,16( 05):26-28
20蔺武,刘心娟,魏南,等.复方鳖甲软肝片抗肝纤维化疗效的系统评价[J].胃肠病学和肝病学杂志,2007,16(1):69-72
21王海燕,朱跃科,申凤俊,等.复方861对DMN损伤性大鼠肝肝纤维中肝脏MMP-2表达的影响[J].中国现代医药杂志,2007,9(4):31
22王宝恩,赵洪涛,王泰玲,等.复方861对肝炎肝纤维化疗效的病理组织学分析[J].中华肝脏病杂志,1997, 5(2)77-78
23蔡卫民.抗肝纤维化药物研究新进展[J].中国药学杂志,2008, 43(3):161-164
24赵长青,吴艺青,徐列明.扶正化瘀胶囊抗肝纤维化的临床疗效和作用机制[J].中西医结合学报,2006,4(5): 467-472
25秦莉,陈欣.扶正化瘀胶囊对慢性乙型肝炎肝纤维化的影响[J].新中医,2008, 40(11):35-36
26徐列明.扶正化瘀胶囊的后续研究[J].药品评价,2008,5(5):198-200,225
27解毒软肝汤对免疫性肝纤维化大鼠血清学及组织学的影响[J].陕西中医,2005,26(12):1381-1383
28李佃贵,裴林,白文忠,等.肝复健胶囊抗免疫性肝纤维化大鼠的实验研究[J].中成药,2007,29(3):346-348
29王珏,裴林,周英,王恩江,郎新宇,李佃贵.藿香、白芍复方逆转慢性肝纤维化的从浊毒论治效果[J].中国临床康复,2006, 10(43):108-111
30林寿宁,朱永苹,雷力民,等.壮肝逐瘀颗粒抗肝纤维化的实验研究[J].广西中医药,2009,32(1):56-58
31梁润英,路嵘.鳖甲抗纤方抗肝纤维化作用的实验[J].中国中医药科技,2004,11(1):16-18
32任映,宋崇顺,尹军祥,等.加味鳖甲煎丸对四氯化碳所致肝纤维化大鼠的治疗作用[J].北京中医药大学学报,2007,30(1):48-50
33高建蓉,张赤志,邵志华,等.鳖甲对肝星状细胞增值影响的研究[J].实用医学杂志,2007,23(11):1618-1620
34陈几香,张建国,张莉,刘京渤.绞股蓝总皂普保肝作用实验研究[J].中国药业,2007,16(13):7-8
35韦登明,余舰,宋琦,等.绞股蓝总苷防治大鼠肝纤维化的实验研究[J].时珍国医国药,2002,13(5):9,257
36吴晓玲,曾维政,蒋明德等.红景天甙对肝纤维化大鼠Samds基因表达的影响[J].第四军医大学学报,2005,26(10):923-926
37吴晓玲,曾维政,蒋明德等.红景天甙对肝纤维化大鼠肝组织ROCK表达的影响[J].世界华人消化杂志,2009,17(8):765-769
38姜兆金,雷明君.甘利欣联合复方丹参治疗慢性乙型肝炎肝纤维化的临床研究[J].肝脏,2007,12(2):159-160
39李校天,杨书良,王军民,等.丹参对肝星状细胞丝裂原活化蛋白激酶通路的抑制作用[J].解放军医学杂志,2006,31(1):22-24
40刘丽,姜慧卿,张晓岚,等.丹参单体IH764-3通过下调H2O2刺激的肝星状细胞FAK水平影响MMP-13和TIMP-1的表达[J].中国应用生理学杂志,2007,23(4):482-486
41吴有莲.苦参碱抗肝纤维化临床研究[J].中药材,2004,27(2):153-154
42卢清,张清波,张继明,等.氧化苦参碱对大鼠肝星状细胞旁分泌活化途径的抑制作用[J].肝脏,2004,9(1):31-33
43陈小亮,李俊,邓子煜.苦参素对肝纤维化大鼠肝脏TGF-β1的调节作用[J].中国药理学通报,2009,25(6):761-764
44杨晴,颜迎春.去纤软肝胶囊治疗乙型肝炎肝纤维化38例[J].中西医结合肝病杂志, 2001,11(5) :300.
45徐列明,刘成,刘平.扁桃苷对大鼠贮脂细胞增殖和产生胶原的影响[J].新消化病学杂志.2007.5(2):84-85
46张晓平,陈建明,强世平,等.山桃仁水煎提取物对肝纤维化小鼠血清I、III型前胶原的降解作用[J].福建中医药,2002,33(4):36
47蔡瑜,沈锡中,王吉耀.甘草酸对肝纤维化基因表达的影响[J].中华医学杂志,2003,83:1122-1125
48董玲,孙剑勇,方国汀,等.甘草酸对转化因子β1刺激肝星状细胞信号转导的作用[J].中华肝脏病杂志,2005,13:828-831
49周朝晖,蔡瑜,沈锡中,等.甘草酸对CCL4肝纤维化大鼠肝组织Smad7免疫组织化学法表达的影响[J].中国临床医学,2006,2:67-69
50陈在忠,王红.川芎嗪抗肝纤维化作用的实验研究[J].中西医结合肝病杂志,2007,7(3):156-158
51华海婴,李艳瑛,戈士文.川芎嗪抗大鼠免疫损伤性肝纤维化作用及机制研究[J].中药药理与临床,2007,23(5):60
52 Zhang FL,Wei YJ,Zhu J, et al. Simultaneous quantitation of three major triterpenoid glycosides in Centella asiatica extracts by high performance liquid chromatography with evaporative light scattering detection[J]. Biomed Chromatogr, 2008, 22(2): 119-124
53杨光,谭家驹,何瑞华等.积雪草酸阻断大鼠肝纤维化的实验研究[J].中国中医基础医学杂志,2009,15(7):540-542
54樊冬梅,任宝琦,刘凤斌,等.中西医结合方案对慢性乙肝抗肝纤维化的临床研究[J].长春中医药大学学报, 2008, 24 (3): 288-289
55黎琮毅,涂燕云,邱琦.中西医结合治疗慢性乙型肝炎32例及对肝纤维化影响[J].福建中医药,2009,40(5):7-8
56梁芳,李长秦,李环.肝康颗粒联合干扰素治疗乙型肝炎肝纤维化临床观察[J].山西中医,2009,25(11):31-33